Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T

In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration of new immunotherapeutic modalities. The fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiaofei, Li, Jiayi, Zheng, Huaijin, Yang, Sen, Hua, Yuze, Huang, Nan, Kleeff, Jorg, Liao, Quan, Wu, Wenming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903509/
https://www.ncbi.nlm.nih.gov/pubmed/36750830
http://dx.doi.org/10.1186/s12943-023-01735-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903509/
https://www.ncbi.nlm.nih.gov/pubmed/36750830
http://dx.doi.org/10.1186/s12943-023-01735-9

Ejemplares similares